Momenta Phama (MNTA) Announces M923 Phase 3 Met Primary Endpoint in Chronic Plaque Psoriasis
Tweet Send to a Friend
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
